Skip to main content
. Author manuscript; available in PMC: 2015 Mar 23.
Published in final edited form as: Mol Cancer Ther. 2013 May 17;12(8):1579–1590. doi: 10.1158/1535-7163.MCT-12-1029

Figure 3. Src inhibition restores TKI sensitivity to WT EGFR in NSCLC cells exposed to CS (even though Src is still bound to EGFR).

Figure 3

A. Serum starved A549 were incubated (or not) for 30’ with 1 μM Erlotinib and 10 μM PP1-PP2 (5-5 μM), combined (or not), and then exposed to either EGF or CS for additional 30’, as before. EGFR was IPed from the total cell lysates and IBed for total receptor, total tyrosine phosphorylation level (p-YEGFR) and specific Tyr site phosphorylation levels (p-Y1173, p-Y1068, p-Y845). B. The graphic shows the quantification of EGFR p-Y1173, normalized to total EGFR in three independent experiments. NS stands for “Not statistically significant”. * = p < 0.05 in respect to control (-).